PCVX

Vaxcyte, Inc.

Healthcare
Biotechnology
$8.59B market cap

Forecast run · Sep 14, 2026Upside rank 1362 of 3,136

Model Signal

ForecastQ Daily Probabilities

38.1%

19.5%

17.6%

Analyst Consensus

Recommendation2.00/5 Buy

Last price$59.47

Price target$105.57

Implied move+77.5%

Analysts11

ForecastQ Portfolios

PCVX is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.